MEDADVISOR LIMITED (MDR)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

MDR - MEDADVISOR LIMITED

FNArena Sector : Healthcare services
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: -5.54
Index:

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.22

30 Nov
2023

-0.005

OPEN

$0.22

-2.22%

HIGH

$0.22

85,400

LOW

$0.22

TARGET
$0.42 90.9% upside
OTHER COMPANIES IN THE SAME SECTOR
ACL . AHX . ALC . BMT . CAJ . DOC . EBO . HLA . HLS . M7T . MPL . MVF . NHF . PSQ . RHC . SHL . SLA .
FNARENA'S MARKET CONSENSUS FORECASTS
MDR: 1
Title FY22
Actual		 FY23
Actual		 FY24
Forecast		 FY25
Forecast
EPS (cps) xxx - 2.1 - 0.1 xxx
DPS (cps) xxx 0.0 0.0 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A N/A xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2023 FactSet UK Limited. All rights reserved
Title 201820192020202120222023
EPS Basic xxxxxxxxxxxxxxx-2.1
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx98.0 M
Book Value Per Share xxxxxxxxxxxxxxx11.0
Net Operating Cash Flow xxxxxxxxxxxxxxx-1.5 M
Net Profit Margin xxxxxxxxxxxxxxx-11.54 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201820192020202120222023
Return on Capital Employed xxxxxxxxxxxxxxx-27.24 %
Return on Invested Capital xxxxxxxxxxxxxxx-21.89 %
Return on Assets xxxxxxxxxxxxxxx-12.97 %
Return on Equity xxxxxxxxxxxxxxx-27.24 %
Return on Total Capital xxxxxxxxxxxxxxx-14.09 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-1.6 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201820192020202120222023
Short-Term Debt xxxxxxxxxxxxxxx1 M
Long Term Debt xxxxxxxxxxxxxxx12 M
Total Debt xxxxxxxxxxxxxxx13 M
Goodwill - Gross xxxxxxxxxxxxxxx47 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx14 M
Price To Book Value xxxxxxxxxxxxxxx2.27

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201820192020202120222023
Capex xxxxxxxxxxxxxxx0.2 M
Capex % of Sales xxxxxxxxxxxxxxx0.18 %
Cost of Goods Sold xxxxxxxxxxxxxxx85 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx20 M
Research & Development xxxxxxxxxxxxxxx8 M
Investments - Total xxxxxxxxxxxxxxx-

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Bell Potter

31/08/2023

1

Buy

$0.42

90.91%

MedAdvisor released FY23 results broadly in line with guidance and Bell Potter's forecasts. Revenue grew 44% year on year with
improvement in gross margin by 9.0% to 61%.

Management emphasised FY24 targets of delivering sustainable revenue growth, positive earnings and improving operating cashflow. The key drivers for this strategy include increasing the patient network, expansion of adherence solutions and integration towards a global ‘One MedAdvisor’ platform.

The shift towards digital engagement is critical in sustaining gross margins in the US, the broker notes, and effectively leveraging the 90m patient reach which will allow MedAdvisor to deliver ongoing growth.

Buy and 42c target retained.

FORECAST
Bell Potter forecasts a full year FY24 dividend of 0.00 cents and EPS of minus -0.10 cents.
Bell Potter forecasts a full year FY25 dividend of 0.00 cents and EPS of 0.60 cents.
Access Stockbroker Research History >

MDR STOCK CHART

FNArena News on MDR

1
Australian Broker Call *Extra* Edition – Nov 09, 2023

Nov 09 2023 - Daily Market Reports
2
Australian Broker Call *Extra* Edition – Nov 07, 2023

Nov 07 2023 - Daily Market Reports
3
Australian Broker Call *Extra* Edition – Sep 08, 2023

Sep 08 2023 - Daily Market Reports
4
FNArena Corporate Results Monitor – 31-08-2023

Aug 31 2023 - Australia
5
Australian Broker Call *Extra* Edition – Aug 02, 2023

Aug 02 2023 - Daily Market Reports

Latest Healthcare services News

1
Treasure Chest: Ramsay Health Care

Oct 26 2023 - Treasure Chest
2
Timing Seems Right For Alcidion Group

Jun 21 2023 - Small Caps
3
No Enthusiasm To Combine ACL & Healius

Mar 21 2023 - Australia
4
Dr Boreham’s Crucible: Alcidion

Dec 13 2022 - Small Caps
5
No Straight Covid-Relief For Ramsay Health Care

Nov 15 2022 - Australia
6
Dr Boreham’s Crucible: Mach7 Technologies

Nov 14 2022 - Small Caps
7
Negative Industry Trends Impact Australian Clinical Labs

Aug 12 2022 - Small Caps
8
Healius Offers Digital Carrot, Base Remains Soft

May 25 2022 - Australia
9
Ramsay Stakes Future on Mental Health

Dec 20 2021 - Australia
10
Ramsay Health Care: Finally A Break-Out

Nov 09 2021 - Technicals